MEDICINA
Departamento
Charles University in Prague
Praga, República ChecaPublicaciones en colaboración con investigadores/as de Charles University in Prague (69)
2024
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
-
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 403, Núm. 10423, pp. 249-260
-
Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells
Science Immunology, Vol. 9, Núm. 91
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591
-
Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Stratification of adolescents across mental phenomena emphasizes the importance of transdiagnostic distress: a replication in two general population cohorts
European Child and Adolescent Psychiatry, Vol. 32, Núm. 5, pp. 797-807
-
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 5, pp. 1172-1177
2022
-
Determinants of patient-reported outcome trajectories and symptomatic recovery in Improving Access to Psychological Therapies (IAPT) services
Psychological Medicine, Vol. 52, Núm. 14, pp. 3231-3240
-
Developing a Web-Based App to Assess Mental Health Difficulties in Secondary School Pupils: Qualitative User-Centered Design Study
JMIR Formative Research, Vol. 6, Núm. 1
-
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Haematologica, Vol. 107, Núm. 10, pp. 2408-2417
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110
-
On Dimensionality, Measurement Invariance, and Suitability of Sum Scores for the PHQ-9 and the GAD-7
Assessment, Vol. 29, Núm. 3, pp. 355-366
-
The impact of the initial COVID-19 outbreak on young adults’ mental health: a longitudinal study of risk and resilience factors
Scientific Reports, Vol. 12, Núm. 1
-
Treating common mental disorder including psychotic experiences in the primary care improving access to psychological therapies programme (the TYPPEX study): protocol for a stepped wedge cluster randomised controlled trial with nested economic and process evaluation of a training package for therapists
BMJ open, Vol. 12, Núm. 6, pp. e056355
2021
-
Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis
The Lancet Psychiatry, Vol. 8, Núm. 7, pp. 589-598